Juvenile Diabetes Research Foundation Canada

2550 Victoria Park Avenue, Suite 800
Toronto, ON M2J 5A9
President & CEO: Dave Prowten
Board Chair: Lorne Shiff

Website: www.jdrf.ca
Charitable Reg. #: 11897 6604 RR0001

Sector: Health

Operating Charity

Charity Rating

Subscribe now for charity ratings

Donor Accountability

Grade: B

The grade is based on the charity's public reporting of the work it does and the results it achieves.

Financial Transparency

Audited financial statements for current and previous years available on the charity's website [ Audited financial statement for most recent year ]

Need for Funding

Funding Reserves Program Costs

Spending Breakdown

Cents to The Cause

♦	♦	♦
			95¢



			75¢
			avg
			65¢


			50¢

2014	2015	2016

For a dollar donated, cents funding the cause after fundraising and admin costs, excluding surplus.

Full-time staff #117

Avg. Compensation $62,794

Top 10 Staff Salary Range

$350k +	0
$300k - $350k	0
$250k - $300k	0
$200k - $250k	1
$160k - $200k	1
$120k - $160k	2
$80k - $120k	6
$40k - $80k	0
< $40k	0

Information from most recent CRA Charities Directorate filings for F2015

About Juvenile Diabetes Research Foundation Canada:

Founded in 1974 by parents of children with diabetes, Juvenile Diabetes Research Foundation Canada (JDRF) is the largest funder and advocate for Type 1 diabetes (T1D) research in Canada. Its focus is to find a cure for T1D and its complications. JDRF reports that 300,000 Canadians live with T1D. On average, T1D management requires 1,460 insulin shots a year. T1D often leads to life-threatening and debilitating complications which may include kidney failure, blindness, heart disease, stroke, nerve damage and amputation. The frequency of T1D among children under the age of 14 is rising, with rates doubling over the last 20 years in children under 5 years old. JDRF funds research focused on three main ideas: cure, prevention and treatment. Its main research focus includes immune therapies, regeneration, replacement, prevention, artificial pancreas, glucose control therapy and complications prevention.

In F2015, Juvenile Diabetes Research Foundation Canada awarded 121 new research grants, funding 200 global institutions and 39 research projects in Canada. The grants also funded 50 active clinical trials globally. In F2015, 350 principal investigators received funding from JDRF.

JDRF’s research surrounding an artificial pancreas is a revolutionary advance in diabetes care. In F2014, the artificial pancreas received USFDA approval. JDRF's research milestones also include beta cell encapsulation (implanting stem cells to "heal" T1D). In F2015, the first cohort of Canadian participants began testing the safety of the encapsulation product. In F2016, JDRF plans to test the tolerability and efficacy of the product, which could allow those with T1D to live free of insulin injections. Finally, JDRF’s stem cell research focuses on converting stem cells into insulin-producing pancreatic cells. This can rapidly reverse diabetes following a transplant.

This is the most recent output data available. As of the date this report was updated, JDRF had yet to publish its annual report for F2016.

Financial Review:

Juvenile Diabetes Research Foundation Canada is a Major 100 charity with donations of $20.1m in F2016. Administrative costs were 22% of revenues and fundraising costs were 47% of donations. For every $1 donated, 32 cents went to the cause. This falls outside of Charity Intelligence’s range for reasonable overhead spending.

The Foundation has funding reserves of $7.3m, of which $86k is donor-endowed. Excluding donor-endowed funds, the Foundation has enough funds on hand to cover just over 11 months of grants and programs.

This charity report is an update that is currently being reviewed by Juvenile Diabetes Research Foundation Canada. Changes and edits may be forthcoming.

Updated on July 24, 2017 by Juliana Badovinac.

Financial Ratios Fiscal year ending December	2016	2015	2014
Administrative costs as % of revenues	21.5%	20.9%	18.7%
Fundraising costs as % of donations	46.8%	48.9%	47.1%
Program cost coverage (%)	93.8%	94.7%	105.7%

Summary Financial Statements All figures in $000s	2016	2015	2014
Donations	20,119	19,963	20,908
Government funding	0	42	0
Lotteries (net)	0	272	427
Investment income	0	128	235
Total revenues	20,119	20,405	21,570
Program costs	1,305	1,118	1,184
Grants	6,482	7,862	8,710
Administrative costs	4,315	4,233	3,997
Fundraising costs	9,407	9,757	9,839
Cash flow from operations	(1,390)	(2,565)	(2,160)
Funding reserves	7,307	8,501	10,455

Note: Ci used government funding amounts recorded in the charity’s T3010 filing with the CRA, which was backed out of donations. At the time of analysis, the charity’s F2016 T3010 filing was not available, so no correction for government funding could be made. Amortization was backed out of administrative costs and included separately as a non-cash expense.

Comments added by the Charity:

These comments refer to an outdated Charity Intelligence profile:

JDRF directs funds to deliver both near-term benefits for people who live with type 1 diabetes and, ultimately, a cure. Our research focus is on two distinct and related aims of science leading to a cure and science leading to better treatments. JDRF also provides outreach support services, volunteer and advocacy opportunities.

Canada’s excellence in diabetes research and breakthroughs continues in the creation of the JDRF Canadian Clinical Trial Network. Launched in 2010 through a partnership with the Government of Canada, JDRF CCTN began as a $33.9M investment to accelerate the testing of new technologies and treatments for Canadians living with type 1 diabetes and its complications.

JDRF is positively impacting the lives and futures of people living with diabetes. Thanks to the support of our generous donors, JDRF has made significant advancements and progress toward positive health outcomes for people living with type 1 diabetes. For example:

JDRF-funded research with industry partners on immune therapies is progressing to the most advanced stages of clinical testing
JDRF now funds over 50 human clinical trials, as opposed to five in 2003.
JDRF is perfecting insulin treatments, a critical component of JDRF’s Artificial Pancreas Project and impact on the daily lives of those living with type 1 diabetes.
Recent advances in diabetic eye disease, funded in part by JDRF, hold the potential to help prevent and reverse eye disease in people with type 1 diabetes.

We remain committed to a cure while investing in better treatments for today.